Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
| Status: | Completed |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 12 - 17 |
| Updated: | 12/12/2018 |
| Start Date: | July 11, 2016 |
| End Date: | January 2, 2018 |
An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal
Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to
SevereScalp Psoriasis
Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to
SevereScalp Psoriasis
- Evaluate the potential of DSXS topical product to suppress HPA axis function in patients
with moderate to severe scalp psoriasis.
- Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product
administered to patients with moderate to severe scalp psoriasis.
with moderate to severe scalp psoriasis.
- Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product
administered to patients with moderate to severe scalp psoriasis.
Inclusion Criteria:
- Male or non-pregnant, non-lactating females 12-17 years of age.
Exclusion Criteria:
- Females who are pregnant, nursing, planning to become pregnant during the duration of
the study, or if of child-bearing potential and sexually active and not prepared to
use appropriate contraceptive methods to avoid pregnancy.
We found this trial at
1
site
Click here to add this to my saved trials
